Abivax SA Sponsored ADR (ABVX) Price & Analysis

Compare

224 Followers

ABVX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$4.77 - $92.91

Previous CloseN/A

Volume62.24K

Average Volume (3M)1.14M

Market Cap

$6.35B

Enterprise Value$513.05M

Total Cash (Recent Filing)$60.95M

Total Debt (Recent Filing)$98.71M

Price to Earnings (P/E)―

Beta2.47

Next Earnings

Dec 15, 2025

EPS Estimate

-0.73

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.89

Shares Outstanding75,573,510

10 Day Avg. Volume1,142,634

30 Day Avg. Volume1,135,987

Financial Highlights & Ratios

PEG Ratio0.14

Price to Book (P/B)10.98

Price to Sales (P/S)41.30

P/FCF Ratio-2.88

Enterprise Value/Market Cap0.08

Enterprise Value/Revenue54.49

Enterprise Value/Gross Profit54.49

Enterprise Value/Ebitda-2.27

Forecast

1Y Price Target

$106.17

Price Target Upside23.51% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

Bulls Say, Bears Say

Bulls Say

Commercial PotentialFeedback from 5 KOLs supports strong commercial potential for obefazimod in UC.

Market PositionObefazimod now has the most compelling late-stage clinical profile for a novel oral agent in ulcerative colitis with potential to address a clear unmet need in the massive ~$30bn market for IBD therapeutics.

Regulatory ApprovalBoth doses of obefazimod met European Medicines Agency co-primary endpoints, strengthening confidence in the potential for regulatory approval.

Bears Say

Dose EfficacyThe lower 25mg QD dose was not statistically significant on clinical remission in ABTECT-2, although other relevant endpoints were significant.

Abivax SA Sponsored ADR News

Abivax price target raised to $101 from $71 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Abivax (ABVX) to $101 from $71 and keeps an Overweight...

1d ago

ABVX

Abivax SA Reports Financial Results and Strategic Advances

Abivax SA Sponsored ADR ( ($ABVX) ) has released its Q2 earnings. Here is a breakdown of the...

4d ago

ABVX

Promising Outlook for Abivax SA: Buy Rating Supported by Strong Clinical Results and Financial Position

Julian Harrison, an analyst from BTIG, maintained the Buy rating on Abivax SA Sponsored ADR. The associated price...

4d ago

ABVX

Abivax Reports Increased Losses but Secures Major Funding in H1 2025

The latest announcement is out from Abivax SA Sponsored ADR ( ($ABVX) ). On September 8, 2025, Abivax...

5d ago

ABVX

Abivax SA Sponsored ADR (ABVX) Q2 Earnings Cheat Sheet

Abivax SA Sponsored ADR (ABVX) is scheduled to report 2nd quarter earnings on 09/08/2025, after the market closes....

7d ago

ABVX

Abivax price target raised to $112 from $70 at Piper Sandler

Piper Sandler raised the firm’s price target on Abivax (ABVX) to $112 from $70 and keeps an Overweight...

2M ago

ABVX

Abivax SA Announces $608.6 Million Public Offering of ADSs

Abivax SA Sponsored ADR ( ($ABVX) ) has provided an announcement. On July 23, 2025, Abivax SA entered...

2M ago

ABVX

Abivax prices 10.2M ADSs at $64.00 in underwritten public offering

Abivax (ABVX) announces the pricing of its previously announced underwritten public offering of 10,156,000 American Depositary Shares, each...

2M ago

ABVX

Abivax 10.16M ADS offering priced at $64.00

Abivax (ABVX) announces the pricing of its previously announced underwritten public offering of 10,156,000 American Depositary Shares, each...

2M ago

ABVX

Abivax SA’s Obefazimod: Strong Phase 3 Results and Promising Market Potential Justify Buy Rating

Abivax SA Sponsored ADR, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Thomas...

2M ago

ABVX

Abivax announces trading resumption of shares on Euronext Paris

Abivax (ABVX) announced the trading resumption of its ordinary shares on the regulated market of Euronext Paris as...

2M ago

ABVX

Why Is Abivax Stock (ABVX) Up 490% Today?

Abivax stock rocketed higher on Wednesday after it posted positive Phase 3 clinical trial data. ...

2M ago

ABVX

Abivax $400M Spot Secondary; price range $62.50-$65.00

Leerink, Piper Sandler, Guggenheim and LifeSci Capital are acting as joint book running managers for the offering. Published...

2M ago

ABVX

Abivax announces $400M ADS offering

Abivax (ABVX) SA announced the launch of an approximately $400M underwritten public offering consisting of a public offering...

2M ago

ABVX

ABVX FAQ

What was Abivax SA Sponsored ADR’s price range in the past 12 months?

Abivax SA Sponsored ADR lowest stock price was $4.77 and its highest was $92.91 in the past 12 months.

What is Abivax SA Sponsored ADR’s market cap?

Abivax SA Sponsored ADR’s market cap is $6.35B.

When is Abivax SA Sponsored ADR’s upcoming earnings report date?

Abivax SA Sponsored ADR’s upcoming earnings report date is Dec 15, 2025 which is in 93 days.

How were Abivax SA Sponsored ADR’s earnings last quarter?

Abivax SA Sponsored ADR released its earnings results on Sep 08, 2025. The company reported -$0.892 earnings per share for the quarter, beating the consensus estimate of -$0.929 by $0.037.

Is Abivax SA Sponsored ADR overvalued?

According to Wall Street analysts Abivax SA Sponsored ADR’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Abivax SA Sponsored ADR pay dividends?

Abivax SA Sponsored ADR does not currently pay dividends.

What is Abivax SA Sponsored ADR’s EPS estimate?

Abivax SA Sponsored ADR’s EPS estimate is -0.73.

How many shares outstanding does Abivax SA Sponsored ADR have?

Abivax SA Sponsored ADR has 75,573,510 shares outstanding.

What happened to Abivax SA Sponsored ADR’s price movement after its last earnings report?

Abivax SA Sponsored ADR reported an EPS of -$0.892 in its last earnings report, beating expectations of -$0.929. Following the earnings report the stock price went down -0.833%.

Which hedge fund is a major shareholder of Abivax SA Sponsored ADR?

Currently, no hedge funds are holding shares in ABVX

Abivax SA Sponsored ADR Stock Smart Score

Outperform

Fundamentals

Return on Equity

-147.48%

Trailing 12-Months

Asset Growth

-41.18%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Abivax SA Sponsored ADR

Abivax SA is a clinical-stage biopharmaceutical company focused on the development of novel therapeutic treatments for inflammatory diseases and viral infections, including its lead product candidate ABX464, which is being investigated for the treatment of ulcerative colitis and other indications. The company operates primarily in the biotechnology sector, leveraging its proprietary technologies to discover and develop innovative therapies that address significant unmet medical needs.

Abivax SA Sponsored ADR (ABVX) Earnings & Revenues

Historic Earnings Reports

ABVX Stock 12 Month Forecast

Average Price Target

$106.17

▲(23.51% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","117":"$117","32.25":"$32.3","60.5":"$60.5","88.75":"$88.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":116,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$116.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":106.17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$106.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":95,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$95.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,32.25,60.5,88.75,117],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,81.99,84.60615384615384,87.2223076923077,89.83846153846153,92.45461538461538,95.07076923076923,97.68692307692308,100.30307692307693,102.91923076923077,105.53538461538461,108.15153846153846,110.7676923076923,113.38384615384615,{"y":116,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,81.99,83.85,85.71,87.57,89.42999999999999,91.28999999999999,93.15,95.00999999999999,96.87,98.73,100.59,102.45,104.31,{"y":106.17,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,81.99,82.99076923076923,83.99153846153845,84.99230769230769,85.99307692307691,86.99384615384615,87.99461538461539,88.99538461538461,89.99615384615385,90.99692307692308,91.9976923076923,92.99846153846154,93.99923076923076,{"y":95,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.56,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.71,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.97,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.48,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.32,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.97,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.68,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.89,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.91,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.35,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.66,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.94,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.99,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >